Skip to main content
Back
Watch Compare

Cordyceps Sunshine Biotech Holdings Co., Ltd.

Data quality: 100%
RAJAF
OTC Manufacturing Chemicals
$9.18
$0.00 (0.00%)
Mkt Cap: 1.02 B
Price
$9.18
Mkt Cap
1.02 B
Day Range
$3.01 — $3.01
52-Week Range
$3.01 — $10.56
Volume
154
Open $3.01
50D / 200D Avg
$9.18
0.00% above
50D / 200D Avg
$9.16
0.20% above

Quick Summary

Key Takeaways

Net margin of 93.35% shows strong profitability
Generating 117,315.0 in free cash flow
P/E of 1238.17 — premium valuation
ROIC of 345.70% — excellent capital efficiency

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-29.59%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC345.70%
Net Margin93.35%
Op. Margin25.54%

Safety

Debt / Equity
N/A
Current Ratio0.04
Interest Coverage8.49

Valuation

PE (TTM)
1238.17
Above sector avg (-1.48)
P/B RatioN/A
EV/EBITDA3615.44
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E 1238.2 -1.5
P/B — 1.6
ROE % — -53.4
Net Margin % 93.4 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -29.59% Revenue Growth (3Y) 40.23%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 882,533.0 Net Income (TTM) 823,860.0
ROE N/A ROA 20.48%
Gross Margin 86.84% Operating Margin 25.54%
Net Margin 93.35% Free Cash Flow (TTM) 117,315.0
ROIC 345.70% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.04
Interest Coverage 8.49 Asset Turnover 0.22
Working Capital -1.41 M Tangible Book Value -182,939
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 1238.17 Forward P/E N/A
P/B Ratio N/A P/S Ratio 1155.86
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 3615.44 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 0.01%
Market Cap 1.02 B Enterprise Value 1.02 B
Per Share
EPS (Diluted TTM) 0.01 Revenue / Share 0.01
FCF / Share 0.00 OCF / Share 0.00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 23.50% FCF Conversion 14.24%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2023 FY2024 FY2022
Revenue 882,533.0 1.25 M 448,785.0
Net Income 823,860.0 -226,258.0 -720,093.0
EPS (Diluted) 0.01 0.00 -0.01
Gross Profit 766,387.0 533,760.0 -66,672.0
Operating Income 225,384.0 -183,913.0 -642,702.0
EBITDA — — —
R&D Expenses 118,444.0 118,444.0 118,444.0
SG&A Expenses — — —
D&A 56,757.0 — 168,899.0
Interest Expense 26,535.0 — 71,772.0
Income Tax -42,221.0 34,957.0 792.0

Balance Sheet

Annual, most recent first
Metric FY2023 FY2024 FY2022
Total Assets 3.42 M 4.62 M 2.10 M
Total Liabilities 3.50 M 5.00 M 3.06 M
Shareholders' Equity -78,731.0 -375,543.0 -951,334.0
Total Debt 431,079.0 431,079.0 —
Cash & Equivalents 15,278.0 37,284.0 16,100.0
Current Assets 330,973.0 601,602.0 501,552.0
Current Liabilities 2.93 M 4.99 M 2.94 M